The trade group says CMS lacks authority to impose GLOBE, which is set to begin January 1.
|Articles|July 24, 2012
Readmissions Double Medicare Patients' Care Costs: Study
Advertisement
Hospital readmissions more than double the cost of care for Medicare beneficiaries, according to an analysis commissioned by a group that represents home health providers.
The study was part of the Alliance for Home Health Quality and Innovation's Clinically Appropriate and Cost-Effective Placement research project, which looked at the impact of admissions and readmissions on Medicare expenditures.
Read the full story:
Source: ModernHealthcare.com
Advertisement
Related to this article
A legal fight over a single amino acid could set retatrutide's exclusivity window, its Medicare negotiation clock, and its competitive future.
CMS finalized Transparency in Coverage updates as a researcher warns ghost rates and missing inpatient data limit payer price files.
A traditional Medicare out-of-pocket (OOP) cap could reduce beneficiaries’ costs but increase annual federal spending by $39 billion to $96 billion.
The FDA approves atezolizumab with a fluoropyrimidine and oxaliplatin as adjuvant therapy for stage III dMMR colon cancer based on the ATOMIC trial.
Washington, DC, clinicians shared how order sets, pharmacist-led dosing, and better handoffs can close iron deficiency gaps in heart failure care.
Michael Mina, MD, PhD, explains Invivyd's accelerated approval path for VYD2311 and how it could change the timing of COVID-19 protection.
The study authors note there is an urgent need for "innovative value-based and alternative payment models of care."
Advertisement
Advertisement
Trending on AJMC
1
5 Things to Know if Retatrutide Is Classified as a Biologic
2
FDA Approves First Symptomatic Dermographism Treatment
3
Predoc and Nebraska Cancer Specialists: Not Letting the Fax Be the Fumble
4
FDA Approves Tucatinib Maintenance for HER2+ Metastatic Breast Cancer
5